These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 10950240)

  • 1. Urinary incontinence: an unrecognised adverse effect with donepezil.
    Hashimoto M; Imamura T; Tanimukai S; Kazui H; Mori E
    Lancet; 2000 Aug; 356(9229):568. PubMed ID: 10950240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Donepezil and athetosis in an elderly patient with Alzheimer's disease.
    Tanaka M; Yokode M; Kita T; Matsubayashi K
    J Am Geriatr Soc; 2003 Jun; 51(6):889-90. PubMed ID: 12757588
    [No Abstract]   [Full Text] [Related]  

  • 3. Drug-induced lupus erythematosus associated with donepezil: a case report.
    Manzo C; Putignano S
    Age Ageing; 2015 Nov; 44(6):1062-3. PubMed ID: 26420637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Donepezil-induced nightmares in mild cognitive impairment.
    Kitabayashi Y; Ueda H; Tsuchida H; Yamashita T; Narumoto J; Fukui K
    Psychiatry Clin Neurosci; 2006 Feb; 60(1):123-4. PubMed ID: 16472374
    [No Abstract]   [Full Text] [Related]  

  • 5. Donepezil for Alzheimer's disease.
    Benjamin B; Burns A
    Expert Rev Neurother; 2007 Oct; 7(10):1243-9. PubMed ID: 17939763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cholinesterase inhibitor treatment and urinary incontinence in Alzheimer's disease.
    Starr JM
    J Am Geriatr Soc; 2007 May; 55(5):800-1. PubMed ID: 17493206
    [No Abstract]   [Full Text] [Related]  

  • 7. Adverse effects of donepezil in treating Alzheimer's disease associated with Down's syndrome.
    Hemingway-Eltomey JM; Lerner AJ
    Am J Psychiatry; 1999 Sep; 156(9):1470. PubMed ID: 10484967
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease.
    Bullock R; Bergman H; Touchon J; Gambina G; He Y; Nagel J; Lane R
    Curr Med Res Opin; 2006 Mar; 22(3):483-94. PubMed ID: 16574032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term safety and efficacy of donepezil in patients with severe Alzheimer's disease: results from a 52-week, open-label, multicenter, extension study in Japan.
    Homma A; Imai Y; Tago H; Asada T; Shigeta M; Iwamoto T; Takita M; Arimoto I; Koma H; Takase T; Ohbayashi T
    Dement Geriatr Cogn Disord; 2009; 27(3):232-9. PubMed ID: 19246907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of donepezil over 3 years: an open-label, multicentre study in patients with Alzheimer's disease.
    Burns A; Gauthier S; Perdomo C
    Int J Geriatr Psychiatry; 2007 Aug; 22(8):806-12. PubMed ID: 17199235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brain injury, cognitive impairment, and donepezil.
    Whitlock JA
    J Head Trauma Rehabil; 1999 Aug; 14(4):424-7. PubMed ID: 10407214
    [No Abstract]   [Full Text] [Related]  

  • 12. Donepezil treatment in severe Alzheimer's disease: a pooled analysis of three clinical trials.
    Winblad B; Black SE; Homma A; Schwam EM; Moline M; Xu Y; Perdomo CA; Swartz J; Albert K
    Curr Med Res Opin; 2009 Nov; 25(11):2577-87. PubMed ID: 19735164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alcohol abuse in an elderly woman taking donepezil for Alzheimer disease.
    Marinho V; Laks J; Engelhardt E; Conn D
    J Clin Psychopharmacol; 2006 Dec; 26(6):683-5. PubMed ID: 17110839
    [No Abstract]   [Full Text] [Related]  

  • 14. [[Donepezil : a new option in the treatment of Alzheimer's disease] ONEPA].
    Azanza JR; Sádaba B; Quetglas EG; Escolar M
    Rev Med Univ Navarra; 1998; 42(2):109-18. PubMed ID: 10420948
    [No Abstract]   [Full Text] [Related]  

  • 15. Unsafe prescription medication switching recommendations.
    Subbiah P; Schwam EM
    Clin Ther; 2001 Dec; 23(12):2050-5. PubMed ID: 11813938
    [No Abstract]   [Full Text] [Related]  

  • 16. Cognitive, global, and functional benefits of donepezil in Alzheimer's disease and vascular dementia: results from large-scale clinical trials.
    Passmore AP; Bayer AJ; Steinhagen-Thiessen E
    J Neurol Sci; 2005 Mar; 229-230():141-6. PubMed ID: 15760632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How the FDA forgot the evidence: the case of donepezil 23 mg.
    Schwartz LM; Woloshin S
    BMJ; 2012 Mar; 344():e1086. PubMed ID: 22442352
    [No Abstract]   [Full Text] [Related]  

  • 18. How many patients complete an adequate trial of donepezil?
    Roe CM; Anderson MJ; Spivack B
    Alzheimer Dis Assoc Disord; 2002; 16(1):49-51. PubMed ID: 11882749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Post-marketing observational study of donepezil].
    Ibach B
    Krankenpfl J; 2005; 43(1-3):25. PubMed ID: 15912820
    [No Abstract]   [Full Text] [Related]  

  • 20. Donepezil for Alzheimer's disease in clinical practice--The DONALD Study. A multicenter 24-week clinical trial in Germany.
    Froelich L; Gertz HJ; Heun R; Heuser I; Jendroska K; Kornhuber J; Kurz A; Mueller-Thomsen T; Ries F; Waechtler C; Metz M; Goebel C
    Dement Geriatr Cogn Disord; 2004; 18(1):37-43. PubMed ID: 15084792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.